Eris Lifesciences Q4 PAT up 21% YoY on strong show by superspecialty biz

Consolidated total income up 13%; robust anti-diabetic sales, new product pipeline, expanded coverage of cardiologists support better numbers

Riding on some of its top brands in the chronic superspecialty segment, formulations manufacturing company Eris Lifesciences Ltd has posted a 21 per cent growth in its consolidated profit after tax (PAT) at Rs 68.25 crore for the quarter ended March 31, 2021.

The company had posted a PAT of Rs 56.27 crore for Q4 of previous fiscal 2019-20. Eris' consolidated total income for the fourth quarter of FY 2020-21 grew by 13 per cent to stand at Rs 280.42 crore, up from Rs 247.5 crore of the corresponding quarter last year.

In a year full of multiple disruptions, Eris Lifesciences clocked